New Randox Adiponectin Test Cleared by TGA will help Global Fight Against Diabetes

CRUMLIN, UNITED KINGDOM - Jul 1, 2014 - The TGA (Australia) has cleared a test developed by Randox Laboratories which allows assessment of the risk of patients developing Type 2 diabetes and Cardiovascular Disease.  Randox’s biochemistry Adiponectin assay uses Latex Enhanced Immunoturbidimetric technology, bringing a superior option for Adiponectin assessment to the clinical diagnostics market.

Adiponectin is a protein hormone produced and secreted exclusively by adipocytes. It regulates the metabolism of lipids and glucose, and influences the body’s response to insulin. Adiponectin also has anti-inflammatory effects on the cells lining the walls of blood vessels. Low levels of Adiponectin therefore can be indicative of insulin resistance (leading to type 2 diabetes) and Cardiovascular Disease. Low adiponectin levels have also been shown to correlate with increased likelihood of a woman developing gestational diabetes in pregnancy.

Randox also offers 2 levels of adiponectin controls as well as an adiponectin calibrator, delivering a complete testing package.

Randox Laboratories Managing Director, Dr Peter FitzGerald said:

“It’s clear that in the 21st Century increasingly sedentary and deskbound lifestyles are driving chronic conditions such as diabetes and cardiovascular disease. 382 million people currently live with diabetes across the world and according to the International Diabetes Federation, this figure is predicted to rise by 55% by 2015. Adiponectin assesses an individual’s risk of development diabetes, and allows resources and treatment to be focused on those patients most at risk. This highly targeted strategy should help to decrease the number the people becoming diabetic, while using resources most effectively.”

Ends

Notes to Editors:

Randox Adiponectin is a Latex Enhanced Immunoturbidimetric assay, wich can be run on multiple clinical chemistry analysers. It has an assay time of approximately 10 minutes, and a correlation of r=0.996 with the ELISA method.

Contact Louise McVicker, Public Relations, for further information atlouise.mcvicker@randox.comor on +44 (0) 28 9445 1016.  www.randox.com

About Randox Laboratories Ltd.

Randox is a global market leader within the in vitro diagnostics industry, developing innovative diagnostic solutions for hospitals, clinical, research and molecular labs, food testing, forensic toxicology, veterinary labs and life sciences. With offices and distribution in over 145 countries, Randox offers customers improved efficiency, quality, cost-effectiveness and flexibility. Randox is committed to revolutionising healthcare on a global scale. With over 1300 employees across 25 offices globally, Randox is dedicated to meeting laboratory testing needs.